Suggestions
James Crowe
Director, Vaccine Researcher, and Professor at Vanderbilt University
James E. Crowe, Jr., MD
James Crowe is a viral immunologist and board-certified pediatric infectious diseases specialist. He is the Director of the Vanderbilt Vaccine Center and a Professor of Pediatrics, Microbiology and Immunology at Vanderbilt University Medical Center.12
Key Positions and Experience
- Director, Vanderbilt Vaccine Center (2006 - Present)
- Professor of Pediatrics, Microbiology and Immunology, Vanderbilt University Medical Center (2006 - Present)
- Founder, IDBiologics (September 2017 - Present), a biotech company developing human monoclonal antibodies for infectious diseases12
- Founder, Corbeau Biotech LLC (August 2009 - August 2017), a biotech company focused on human monoclonal antibody development1
Education and Training
- MD, University of North Carolina at Chapel Hill
- Pediatrics residency, University of North Carolina at Chapel Hill
- Postdoctoral Fellowship in Virology, Immunology and Vaccines, National Institutes of Health (1990-1995)
- Infectious diseases fellowship, Vanderbilt University (1996)2
Awards and Honors
- Elected to the National Academy of Medicine (2014) and National Academy of Inventors (2017)
- Recipient of numerous awards including the Judson Infectious Daland Prize, Oswald Avery Award, E. Mead Johnson Award, Outstanding Investigator Award, and the inaugural 2019 Merck Future Insight Prize2
- His research team was selected as Best Academic Research Team at the 11th Annual Vaccine Industry Excellence Awards2
Dr. Crowe's laboratory has published over 300 papers in high-impact journals and his research focuses on viral immunology and antibody sciences, with the goal of discovering new mechanisms of immunity to develop novel therapeutics and vaccines.2
Highlights
The good news is that we already have isolated and characterized human mAbs for Mpox virus (see our Cell paper at https://lnkd.in/guQGjjg4), which has escalated again. This time the outbreak is caused by a clade I virus, and unfortunately the strain is resistant to the one small molecule drug that was useful. Mpox was declared a public health emergency in Africa this week.
The logic of our AHEAD100 program (making mAbs for all emerging viruses before outbreaks occur) seems ever more obvious. The bad news is that even though we have been working on pox antibodies since 1998, in typical panic/neglect fashion, the research funding climate for this work has been sparse and sporadic. Nevertheless we have good antibodies in hand (from survivors of a previous mpox outbreak in the US!), in vivo efficacy data in small animals and NHPs, and partners in industry, government and academia to get this done.
Still, its a bit of a scramble to get these into clinical trials because of the complexity.
#AHEAD100 #mpox #antibodies
Our local news team published a nice summary of our ongoing hantavirus antibody sprint. We even gave the team a 5-minute break to get a group photo. We're still sprinting on X.com at @VUMC_Vaccines #AHEAD100 #antibodies #hantavirus
